Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

ClinicalTrials.gov ID: NCT05001880

Public ClinicalTrials.gov record NCT05001880. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.

Study identification

NCT ID
NCT05001880
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
66 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 21, 2022
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027
Last update posted
Aug 12, 2026

2022 – 2027

United States locations

U.S. sites
40
U.S. states
11
U.S. cities
34
Facility City State ZIP Site status
Mayo Clinic Hospital in Arizona Phoenix Arizona 85054 Suspended
Alliance for Clinical Trials in Oncology Chicago Illinois 60606 Recruiting
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 Recruiting
Carle at The Riverfront Danville Illinois 61832 Recruiting
Carle Physician Group-Effingham Effingham Illinois 62401 Recruiting
Carle Physician Group-Mattoon/Charleston Mattoon Illinois 61938 Recruiting
Carle Cancer Center Urbana Illinois 61801 Recruiting
The Carle Foundation Hospital Urbana Illinois 61801 Recruiting
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 Active, not recruiting
Sanford Joe Lueken Cancer Center Bemidji Minnesota 56601 Recruiting
Mercy Hospital Coon Rapids Minnesota 55433 Recruiting
Fairview Southdale Hospital Edina Minnesota 55435 Recruiting
Unity Hospital Fridley Minnesota 55432 Active, not recruiting
Abbott-Northwestern Hospital Minneapolis Minnesota 55407 Recruiting
Mayo Clinic in Rochester Rochester Minnesota 55905 Recruiting
Park Nicollet Clinic - Saint Louis Park Saint Louis Park Minnesota 55416 Recruiting
Regions Hospital Saint Paul Minnesota 55101 Recruiting
United Hospital Saint Paul Minnesota 55102 Recruiting
Rice Memorial Hospital Willmar Minnesota 56201 Recruiting
Sanford Cancer Center Worthington Worthington Minnesota 56187 Recruiting
Sanford Bismarck Medical Center Bismarck North Dakota 58501 Recruiting
Sanford Broadway Medical Center Fargo North Dakota 58122 Recruiting
Sanford Roger Maris Cancer Center Fargo North Dakota 58122 Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 Recruiting
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 Recruiting
Sanford Cancer Center Oncology Clinic Sioux Falls South Dakota 57104 Recruiting
Sanford USD Medical Center - Sioux Falls Sioux Falls South Dakota 57117-5134 Recruiting
UT MD Anderson - The Woodlands Conroe Texas 77384 Recruiting
UT MD Anderson Cancer Center Houston Texas 77030 Recruiting
UT MD Anderson - West Houston Houston Texas 77079 Recruiting
UT MD Anderson - League City League City Texas 77573 Recruiting
UT MD Anderson - Sugar Land Sugar Land Texas 77478 Recruiting
ThedaCare Regional Cancer Center Appleton Wisconsin 54911 Recruiting
Marshfield Medical Center-EC Cancer Center Eau Claire Wisconsin 54701 Recruiting
Marshfield Medical Center-Marshfield Marshfield Wisconsin 54449 Recruiting
Marshfield Medical Center - Minocqua Minocqua Wisconsin 54548 Recruiting
Marshfield Medical Center-Rice Lake Rice Lake Wisconsin 54868 Recruiting
Marshfield Medical Center-River Region at Stevens Point Stevens Point Wisconsin 54482 Recruiting
Marshfield Medical Center - Weston Weston Wisconsin 54476 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05001880, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2026 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05001880 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →